FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2086779454> ?p ?o ?g. }

• W2086779454 endingPage "520" @default.
• W2086779454 startingPage "515" @default.
• W2086779454 abstract "Objective To evaluate the efficacy of imidafenacin for nocturia and nocturnal polyuria in patients with overactive bladder. Materials and Methods A stratified analysis was conducted on data from a phase III randomized, double-blind, controlled trial of imidafenacin performed at 158 centers in Japan. The subjects received imidafenacin (0.1 mg) twice daily (group I) or placebo twice daily (group P). The 24-hour urine volume, daytime and nighttime voiding frequency, and volume voided/micturition were evaluated from 3-day voiding diaries recorded every 4 weeks during the 12-week study period. Longitudinal data analysis was performed, with all values expressed as the least squares mean ± standard error. Results A total of 46 patients (mean age 66.54 ± 9.38 years, 9 men and 37 women) with nocturia and nocturnal polyuria (>33% of urine production at night) were enrolled. Group I (n = 35) and group P (n = 11) showed no baseline differences in the daily voided volume, concomitant diseases, age, or body weight. However, the average daily number of micturitions differed (11.22 ± 2.17 vs 14.45 ± 2.85). Therefore, longitudinal data analysis was performed for each micturition pattern. After 12 weeks of treatment, nighttime micturition was significantly less frequent in group I than in group P (P = .0292), and the nocturnal percentage of 24-hour production was significantly smaller (P = .0053). The interval to the first nighttime void was significantly longer in group I than in group P, but no difference was found in the first nighttime voided volume. Conclusion The novel antimuscarinic agent, imidafenacin, decreases the number of urinations and reduces nocturnal urine production, thereby improving both nocturia and nocturnal polyuria. To evaluate the efficacy of imidafenacin for nocturia and nocturnal polyuria in patients with overactive bladder. A stratified analysis was conducted on data from a phase III randomized, double-blind, controlled trial of imidafenacin performed at 158 centers in Japan. The subjects received imidafenacin (0.1 mg) twice daily (group I) or placebo twice daily (group P). The 24-hour urine volume, daytime and nighttime voiding frequency, and volume voided/micturition were evaluated from 3-day voiding diaries recorded every 4 weeks during the 12-week study period. Longitudinal data analysis was performed, with all values expressed as the least squares mean ± standard error. A total of 46 patients (mean age 66.54 ± 9.38 years, 9 men and 37 women) with nocturia and nocturnal polyuria (>33% of urine production at night) were enrolled. Group I (n = 35) and group P (n = 11) showed no baseline differences in the daily voided volume, concomitant diseases, age, or body weight. However, the average daily number of micturitions differed (11.22 ± 2.17 vs 14.45 ± 2.85). Therefore, longitudinal data analysis was performed for each micturition pattern. After 12 weeks of treatment, nighttime micturition was significantly less frequent in group I than in group P (P = .0292), and the nocturnal percentage of 24-hour production was significantly smaller (P = .0053). The interval to the first nighttime void was significantly longer in group I than in group P, but no difference was found in the first nighttime voided volume. The novel antimuscarinic agent, imidafenacin, decreases the number of urinations and reduces nocturnal urine production, thereby improving both nocturia and nocturnal polyuria." @default.
• W2086779454 created "2016-06-24" @default.
• W2086779454 creator A5033408219 @default.
• W2086779454 creator A5048355512 @default.
• W2086779454 creator A5071062016 @default.
• W2086779454 date "2013-09-01" @default.
• W2086779454 modified "2023-10-17" @default.
• W2086779454 title "Imidafenacin, an Antimuscarinic Agent, Improves Nocturia and Reduces Nocturnal Urine Volume" @default.
• W2086779454 cites W1489359480 @default.
• W2086779454 cites W1558239558 @default.
• W2086779454 cites W1597433473 @default.
• W2086779454 cites W1966439653 @default.
• W2086779454 cites W1980811042 @default.
• W2086779454 cites W1987989641 @default.
• W2086779454 cites W1997437017 @default.
• W2086779454 cites W2028771001 @default.
• W2086779454 cites W2048007562 @default.
• W2086779454 cites W2073965418 @default.
• W2086779454 cites W2104094798 @default.
• W2086779454 cites W2121255319 @default.
• W2086779454 cites W2157543411 @default.
• W2086779454 doi "https://doi.org/10.1016/j.urology.2013.05.017" @default.
• W2086779454 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23876590" @default.
• W2086779454 hasPublicationYear "2013" @default.
• W2086779454 type Work @default.
• W2086779454 sameAs 2086779454 @default.
• W2086779454 citedByCount "18" @default.
• W2086779454 countsByYear W20867794542014 @default.
• W2086779454 countsByYear W20867794542015 @default.
• W2086779454 countsByYear W20867794542016 @default.
• W2086779454 countsByYear W20867794542018 @default.
• W2086779454 countsByYear W20867794542019 @default.
• W2086779454 countsByYear W20867794542020 @default.
• W2086779454 countsByYear W20867794542021 @default.
• W2086779454 countsByYear W20867794542023 @default.
• W2086779454 crossrefType "journal-article" @default.
• W2086779454 hasAuthorship W2086779454A5033408219 @default.
• W2086779454 hasAuthorship W2086779454A5048355512 @default.
• W2086779454 hasAuthorship W2086779454A5071062016 @default.
• W2086779454 hasConcept C126322002 @default.
• W2086779454 hasConcept C126894567 @default.
• W2086779454 hasConcept C134018914 @default.
• W2086779454 hasConcept C142724271 @default.
• W2086779454 hasConcept C175768497 @default.
• W2086779454 hasConcept C204787440 @default.
• W2086779454 hasConcept C2777333188 @default.
• W2086779454 hasConcept C2777334680 @default.
• W2086779454 hasConcept C2778941218 @default.
• W2086779454 hasConcept C2780026642 @default.
• W2086779454 hasConcept C2780180277 @default.
• W2086779454 hasConcept C555293320 @default.
• W2086779454 hasConcept C71924100 @default.
• W2086779454 hasConcept C77411442 @default.
• W2086779454 hasConceptScore W2086779454C126322002 @default.
• W2086779454 hasConceptScore W2086779454C126894567 @default.
• W2086779454 hasConceptScore W2086779454C134018914 @default.
• W2086779454 hasConceptScore W2086779454C142724271 @default.
• W2086779454 hasConceptScore W2086779454C175768497 @default.
• W2086779454 hasConceptScore W2086779454C204787440 @default.
• W2086779454 hasConceptScore W2086779454C2777333188 @default.
• W2086779454 hasConceptScore W2086779454C2777334680 @default.
• W2086779454 hasConceptScore W2086779454C2778941218 @default.
• W2086779454 hasConceptScore W2086779454C2780026642 @default.
• W2086779454 hasConceptScore W2086779454C2780180277 @default.
• W2086779454 hasConceptScore W2086779454C555293320 @default.
• W2086779454 hasConceptScore W2086779454C71924100 @default.
• W2086779454 hasConceptScore W2086779454C77411442 @default.
• W2086779454 hasIssue "3" @default.
• W2086779454 hasLocation W20867794541 @default.
• W2086779454 hasLocation W20867794542 @default.
• W2086779454 hasOpenAccess W2086779454 @default.
• W2086779454 hasPrimaryLocation W20867794541 @default.
• W2086779454 hasRelatedWork W2013508761 @default.
• W2086779454 hasRelatedWork W2331661321 @default.
• W2086779454 hasRelatedWork W2334249710 @default.
• W2086779454 hasRelatedWork W2379553116 @default.
• W2086779454 hasRelatedWork W2903660077 @default.
• W2086779454 hasRelatedWork W3029816848 @default.
• W2086779454 hasRelatedWork W3031313022 @default.
• W2086779454 hasRelatedWork W3182605385 @default.
• W2086779454 hasRelatedWork W3212015874 @default.
• W2086779454 hasRelatedWork W4206166447 @default.
• W2086779454 hasVolume "82" @default.
• W2086779454 isParatext "false" @default.
• W2086779454 isRetracted "false" @default.
• W2086779454 magId "2086779454" @default.
• W2086779454 workType "article" @default.